Paediatric haemophilia with inhibitors: Existing management options, treatment gaps and unmet needs

Haemophilia

Volumn 15, Issue 5, 2009, Pages 983-989

  Santagostino, Elena ^a   Morfini, M ^b   Auerswald, G K H ^c   Benson, G M ^d   Salek S Z ^e   Lambert, T ^f   Salaj, P ^g   Jimenez Yuste, V ^h   Ljung, R C R ⁱ  

^a UNIVERSITY OF MILAN   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c KLINIKUM BREMEN MITTE   (Germany)

^d Northern Ireland Haemophilia Comprehensive Care Centre   (Ireland)

^e University Hospital Centre   (Croatia)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^g INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^h HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

ⁱ LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Activated prothrombin complex concentrate; Haemophilia; Inhibitors; Paediatric; Prophylaxis; Recombinant activated factor VII

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; NEUTRALIZING ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ABSENTEEISM; ANTIBODY TITER; ARTHROPATHY; BLEEDING; CHILD HEALTH; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; HEMARTHROSIS; HEMOPHILIA; HOSPITALIZATION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGICAL TOLERANCE INDUCTION; JOINT FUNCTION; PEDIATRICS; PHYSICAL DEVELOPMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE; REVIEW; RISK FACTOR; RISK REDUCTION; SINGLE DRUG DOSE; SOCIAL LIFE; SOCIAL STATUS;

BLOOD COAGULATION FACTORS; CHILD; EVIDENCE-BASED PRACTICE; FACTOR VIIA; HEMARTHROSIS; HEMOPHILIA A; HUMANS; MALE; NEEDS ASSESSMENT; QUALITY OF LIFE; RECOMBINANT PROTEINS;

EID: 69949096687     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.01999.x     Document Type: Review

References (41)

1. Keeling D, Tait C, Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia 2008; 14: 671-84.
2. Berntorp E, Shapiro A, Astermark J et al. Inhibitor treatment in haemophilias A and B: Summary statement for the 2006 international consensus conference. Haemophilia 2006; 12 (Suppl 6): 1-7.
3. Santagostino E, Mancuso ME, Rocino A et al. Environmental risk factors for inhibitor development in children with haemophilia A: A case-control study. Br J Haematol 2005; 130: 422-7.
4. Chalmers EA, Brown SA, Keeling D et al. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia 2007; 13: 149-55.
5. Gouw SC, van der Bom JG, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: The CANAL cohort study. Blood 2007; 109: 4648-54.
6. Dimichele D. Inhibitors: Resolving diagnostic and therapeutic dilemmas. Haemophilia 2002; 8: 280-7.
7. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: A systematic review. Haemophilia 2003; 9: 418-35.
8. Soucie JM, Cianfrini C, Janco RL et al. Joint range-of-motion limitations among young males with hemophilia: Prevalence and risk factors. Blood 2004; 103: 2467-73.
9. Morfini M, Haya S, Tagariello G et al. European Study on Orthopaedic Status of haemophilia patients with inhibitors. Haemophilia 2007; 13: 606-12.
10. Teitel J, Berntorp E, Collins P et al. A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors. Haemophilia 2007; 13: 256-63.
11. DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: Consensus recommendations. Haemophilia 2007; 13(Suppl 1): 1-22.
12. Unuvar A, Kavakli K, Baytan B et al. Low-dose immune tolerance induction for paediatric haemophilia patients with factor VIII inhibitors. Haemophilia 2008; 14: 315-22.
13. Astermark J, Rocino A, Von Depka M et al. Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors. Haemophilia 2007; 13: 38-45.
14. Blatny J, Kohlerova S, Zapletal O, Fiamoli V, Penka M, Smith O. Prophylaxis with recombinant factor VIIa for the management of bleeding episodes during immune tolerance treatment in a boy with severe haemophilia A and high-response inhibitors. Haemophilia 2008; 14: 1140-2.
15. Barnes C, Rivard GE, Poon MC et al. Canadian multi-institutional survey of immune tolerance therapy (ITT) - experience with the use of recombinant factor VIII for ITT. Haemophilia 2006; 12: 1-6.
16. Hay CR, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: A guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol 2006; 133: 591-605.
17. Santagostino E, Gringeri A, Mannucci PM. State of care for hemophilia in pediatric patients. Paediatr Drugs 2002; 4: 149-57.
18. Kurnik K, Thomas AE. Meeting report: Ninth and tenth workshops of the European Paediatric Network for Haemophilia Management (PedNet). Haemophilia 2007; 13: 658-62.
19. Lloyd Jones M, Wight J, Paisley S, Knight C. Control of bleeding in patients with haemophilia A with inhibitors: A systematic review. Haemophilia 2003; 9: 464-520.
20. Konkle BA, Ebbesen LS, Erhardtsen E et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5: 1904-13.
21. Leissinger CA, Becton DL, Ewing NP, Valentino LA. Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors. Haemophilia 2007; 13: 249-55.
22. Obergfell A, Auvinen MK, Mathew P. Recombinant activated factor VII for haemophilia patients with inhibitors undergoing orthopaedic surgery: A review of the literature. Haemophilia 2008; 14: 233-41.
23. Key NS, Aledort LM, Beardsley D et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912-8.
24. Kavakli K, Makris M, Bulent Z et al. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. Thromb Haemost 2006; 95: 600-5.
25. Sjamsoedin LJ, Heijnen L, Mauser-Bunschoten EP et al. The effect of activated prothrombincomplex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. N Engl J Med 1981; 305: 717-21.
26. Negrier C, Goudemand J, Sultan Y et al. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. Thromb Haemost 1997; 77: 1113-9.
27. Astermark J, Donfield SM, DiMichele DM et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: The FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109: 546-51.
28. Santagostino E, Mancuso ME, Rocino A, Mancuso G, Scaraggi F, Mannucci PM. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost 2006; 4: 367-71.
29. Young G, Shafer FE, Rojas P, Seremetis S. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: A randomized comparison. Haemophilia 2008; 14: 287-94.
30. HemoRec registry web site. Available at: http://www.hemorec.com (last accessed on 28 October 2008).
31. Fischer K, van der Bom JG, Molho P et al. Prophylactic versus on-demand treatment strategies for severe haemophilia: A comparison of costs and long-term outcome. Haemophilia 2002; 8: 745-52.
32. Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
33. Yee TT, Beeton K, Griffioen A et al. Experience of prophylaxis treatment in children with severe haemophilia. Haemophilia 2002; 8: 76-82.
34. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
35. Rodriguez-Merchan EC, Hedner U, Heijnen L et al. Prevention of haemophilic arthropathy during childhood. May common orthopaedic management be extrapolated from patients without inhibitors to patients with inhibitors? Haemophilia 2008; 14(Suppl 6): 68-81.
36. Leissinger CA. Prevention of bleeds in hemophilia patients with inhibitors: Emerging data and clinical direction. Am J Hematol 2004; 77: 187-93.
37. Young G, McDaniel M, Nugent DJ. Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors. Haemophilia 2005; 11: 203-7.
38. Morfini M, Auerswald G, Kobelt RA et al. Prophylactic treatment of haemophilia patients with inhibitors: Clinical experience with recombinant factor VIIa in European Haemophilia Centres. Haemophilia 2007; 13: 502-7.
39. Schramm W, Royal S, Kroner B et al. Clinical outcomes and resource utilization associated with haemophilia care in Europe. Haemophilia 2002; 8: 33-43.
40. Hoots WK, Ebbesen LS, Konkle BA et al. Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors. Haemophilia 2008; 14: 466-75.
41. Bysted BV, Scharling B, Møller T, Hansen BL. A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25 degrees C stable formulation. Haemophilia 2007; 13: 527-32.